NASDAQ: BGNE | Healthcare / Biotechnology / China |
187.49 | +0.5500 | +0.29% | Vol 209.56K | 1Y Perf -3.92% |
Dec 1st, 2023 16:00 DELAYED |
BID | 185.00 | ASK | 192.70 | ||
Open | 186.94 | Previous Close | 186.94 | ||
Pre-Market | - | After-Market | 187.49 | ||
- - | - -% |
Target Price | 245.60 | Analyst Rating | Strong Buy 1.44 | |
Potential % | 30.99 | Finscreener Ranking | ★★★★ 54.08 | |
Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★ 45.69 | |
Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★★+ 47.48 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 24.93 | Earnings Rating | Strong Buy | |
Market Cap | 19.61B | Earnings Date | 8th Nov 2023 | |
Alpha | 0.01 | Standard Deviation | 0.14 | |
Beta | 0.63 |
Today's Price Range 186.11189.22 | 52W Range 156.56280.62 | 5 Year PE Ratio Range -36.70-17.60 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Neutral |
Performance | |||
---|---|---|---|
1 Week | 1.20% | ||
1 Month | 3.11% | ||
3 Months | -10.52% | ||
6 Months | -16.35% | ||
1 Year | -3.92% | ||
3 Years | -24.16% | ||
5 Years | 21.94% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -37.69 | |||
ROE last 12 Months | -56.13 | |||
ROA (5Y Avg) | -11.13 | |||
ROA last 12 Months | -37.57 | |||
ROC (5Y Avg) | -38.14 | |||
ROC last 12 Months | -44.67 | |||
Return on invested Capital Q | -9.87 | |||
Return on invested Capital Y | -10.65 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 3.30 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-11.60 | ||||
5.48 | ||||
24.68 | ||||
605.70 | ||||
-17.30 | ||||
-16.70 | ||||
5.52 | ||||
44.78 | ||||
20.67B | ||||
Forward PE | -31.25 | |||
PEG | -0.52 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.70 | ||||
4.10 | ||||
0.05 | ||||
0.15 | ||||
- | ||||
Leverage Ratio | 1.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-33.10 | ||||
-151.40 | ||||
-146.50 | ||||
-280.90 | ||||
-86.01 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.04B | ||||
9.96 | ||||
218.50 | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -3.23 | -3.64 | -12.69 |
Q01 2023 | -3.94 | -3.34 | 15.23 |
Q04 2022 | -4.22 | -4.29 | -1.66 |
Q03 2022 | -4.02 | -5.39 | -34.08 |
Q02 2022 | -4.23 | -5.56 | -31.44 |
Q01 2022 | -4.52 | -4.24 | 6.19 |
Q04 2021 | -4.79 | -6.16 | -28.60 |
Q03 2021 | -4.82 | -4.46 | 7.47 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2023 QR | -1.29 | 40.55 | Positive |
12/2023 QR | -3.66 | -34.07 | Negative |
12/2023 FY | -6.99 | 44.48 | Positive |
12/2024 FY | -5.91 | 27.57 | Positive |
Next Report Date | - |
Estimated EPS Next Report | -3.16 |
Estimates Count | 3 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 209.56K |
Shares Outstanding | 104.58K |
Shares Float | 76.97M |
Trades Count | 6.11K |
Dollar Volume | 39.32M |
Avg. Volume | 196.13K |
Avg. Weekly Volume | 161.40K |
Avg. Monthly Volume | 220.39K |
Avg. Quarterly Volume | 206.59K |
BeiGene Ltd. (NASDAQ: BGNE) stock closed at 186.94 per share at the end of the most recent trading day (a 2.08% change compared to the prior day closing price) with a volume of 186.74K shares and market capitalization of 19.61B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5300 people. BeiGene Ltd. CEO is John V. Oyler.
The one-year performance of BeiGene Ltd. stock is -3.92%, while year-to-date (YTD) performance is -15%. BGNE stock has a five-year performance of 21.94%. Its 52-week range is between 156.56 and 280.6199, which gives BGNE stock a 52-week price range ratio of 24.93%
BeiGene Ltd. currently has a PE ratio of -11.60, a price-to-book (PB) ratio of 5.48, a price-to-sale (PS) ratio of 24.68, a price to cashflow ratio of 605.70, a PEG ratio of -0.52, a ROA of -37.57%, a ROC of -44.67% and a ROE of -56.13%. The company’s profit margin is -86.01%, its EBITDA margin is -146.50%, and its revenue ttm is $1.04 Billion , which makes it $9.96 revenue per share.
Of the last four earnings reports from BeiGene Ltd., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-3.16 for the next earnings report. BeiGene Ltd.’s next earnings report date is -.
The consensus rating of Wall Street analysts for BeiGene Ltd. is Strong Buy (1.44), with a target price of $245.6, which is +30.99% compared to the current price. The earnings rating for BeiGene Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BeiGene Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BeiGene Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.35, ATR14 : 6.56, CCI20 : -28.96, Chaikin Money Flow : -0.09, MACD : 0.54, Money Flow Index : 48.40, ROC : -6.11, RSI : 51.43, STOCH (14,3) : 29.91, STOCH RSI : 1.00, UO : 51.77, Williams %R : -70.09), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BeiGene Ltd. in the last 12-months were: Capital Advisors, Ltd. Hillhouse (Sold 4 154 817 shares of value $823 480 568 ), HHLR ADVISORS, LTD. (Sold 4 154 817 shares of value $823 490 197 ), Oyler John (Sold 8 552 shares of value $2 127 538 ), Sanders Corazon (Sold 100 shares of value $18 074 ), Sanders Corazon (Corsee) D. (Sold 578 shares of value $105 381 ), Wang Julia Aijun (Sold 1 312 shares of value $238 341 ), Wang Lai (Sold 3 019 shares of value $583 636 ), Wang Xiaodong (Sold 811 620 shares of value $-8 793 ), Wang Xiaodong (Sold 61 771 shares of value $14 144 437 ), Wu Xiaobin (Sold 7 253 shares of value $1 565 482 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
BeiGene Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.
CEO: John V. Oyler
Telephone: +1 345 949-4123
Address: c/o Mourant Governance Services (Cayman) Limited, Grand Cayman KY1-1108, , KY
Number of employees: 5 300
Thu, 23 Nov 2023 11:50 GMT Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Karuna Therapeutics (KRTX) and Theseus Pharmaceuticals (THRX)
- TipRanks. All rights reserved.Mon, 16 Oct 2023 13:00 GMT Analysts Top Healthcare Picks: BeiGene (BGNE), Moderna (MRNA)
- TipRanks. All rights reserved.Mon, 14 Aug 2023 13:01 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Agilon Health (AGL), BeiGene (BGNE) and Trevi Therapeutics (TRVI)
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.